VEGFA and cervical carcinoma: As a monoclonal antibody to humanized VEGF, the GOG240 clinical trial showed that bevacizumab could significantly prolong the survival period of recurrent and metastatic cervical cancer, indicating that anti-angiogenic clinical treatment of cervical cancer could be beneficial.